First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
Authors
Keywords
Metastatic melanoma, BRAFV600, Immunotherapy, Target therapy, First line
Journal
CANCER TREATMENT REVIEWS
Volume 99, Issue -, Pages 102253
Publisher
Elsevier BV
Online
2021-06-18
DOI
10.1016/j.ctrv.2021.102253
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma
- (2021) Claudia Trojaniello et al. CURRENT OPINION IN ONCOLOGY
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
- (2020) Paolo A. Ascierto et al. EUROPEAN JOURNAL OF CANCER
- Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD.
- (2020) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.
- (2020) Helen Gogas et al. JOURNAL OF CLINICAL ONCOLOGY
- ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee
- (2020) U. Keilholz et al. ANNALS OF ONCOLOGY
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
- (2020) P. Nathan et al. ANNALS OF ONCOLOGY
- LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)
- (2020) P.A. Ascierto et al. ANNALS OF ONCOLOGY
- Function and evolution of B-Raf loop dynamics relevant to cancer recurrence under drug inhibition
- (2020) Gregory A. Babbitt et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
- (2020) Pier Francesco Ferrucci et al. Journal for ImmunoTherapy of Cancer
- Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry
- (2020) M.C.T. van Zeijl et al. EUROPEAN JOURNAL OF CANCER
- Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma
- (2019) Justine V Cohen et al. CLINICAL CANCER RESEARCH
- Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis
- (2019) Qiaofen Fu et al. OncoImmunology
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- (2019) Antoni Ribas et al. NATURE MEDICINE
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2019) O Michielin et al. ANNALS OF ONCOLOGY
- 1312PDSafety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): A single center phase II study
- (2019) E M Burton et al. ANNALS OF ONCOLOGY
- Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
- (2019) Christian Menzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Data Supporting Antitumor Activity of PD-1 Blockade
- (2018) Michael A. Curran CANCER JOURNAL
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological effects of BRAF+MEK inhibition
- (2018) Paolo A. Ascierto et al. OncoImmunology
- Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
- (2017) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma
- (2017) Joao Paulo da Silveira Nogueira Lima et al. Cancer Medicine
- Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with knownBRAFmutation status
- (2016) A.L. Frauchiger et al. BRITISH JOURNAL OF DERMATOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
- (2016) Antoine Millet et al. MEDICINAL RESEARCH REVIEWS
- Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity
- (2016) Charles H. Adelmann et al. Oncotarget
- Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
- (2016) Marcel A. Deken et al. OncoImmunology
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- New Strategies in Melanoma: Entering the Era of Combinatorial Therapy
- (2015) R. J. Sullivan et al. CLINICAL CANCER RESEARCH
- 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
- (2015) C. Robert et al. EUROPEAN JOURNAL OF CANCER
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
- (2015) Jean Jacques Grob et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
- (2015) David R. Minor et al. Pigment Cell & Melanoma Research
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
- (2015) S. D. Bradley et al. Cancer Immunology Research
- Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
- (2015) Blanca Homet Moreno et al. OncoImmunology
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Resistance to BRAF-targeted therapy in melanoma
- (2013) Ryan J. Sullivan et al. EUROPEAN JOURNAL OF CANCER
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
- (2012) C. Liu et al. CLINICAL CANCER RESEARCH
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now